Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/0000222532

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000221604

Opinion/decision on a Paediatric investigation plan (PIP): Comirnaty, famtozinameran,riltozinameran,tozinameran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000221583

Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000225594

EMA/PE/0000221462

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221296

Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221213

Opinion/decision on a Paediatric investigation plan (PIP): Velsipity, etrasimod, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000184081

Opinion/decision on a Paediatric investigation plan (PIP): Ebvallo, tabelecleucel, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000183827

Opinion/decision on a Paediatric investigation plan (PIP): Livtencity, Maribavir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000182607